San Diego-centered Viking Therapeutics marked itself as a serious competitor within the weight loss drug sector in February soon after revealing promising information from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered to be a weekly injection As well as in March the c